Compare British American Tobacco PLC (BTI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs BIO-TECHNE Corp — how do they compare? British American Tobacco PLC trades at $56.84 (market cap $122.96B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: British American Tobacco PLC is far larger — about 10.9× BIO-TECHNE Corp's market cap, and British American Tobacco PLC pays the higher dividend (5.85%). Which is the better fit depends on your goals.
| BTI | TECH | |
|---|---|---|
Market Cap | $122.96B | $11.24B |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $72.29 |
52-Week Low | $50.39 | $43.31 |
Enterprise Value | $166.84B | $11.32B |
Dividend Yield | 5.85% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTI trades at $59.33, up 1.02% today, with a bearish technical signal but strong fundamentals including a P/E of 15.15, net income margin of 24.99%, and consistent earnings beats. Recent news highlights growth in next-generation products like Velo, though restructuring and regulatory pressures persist.
The outlook is mixed: valuation appears attractive with a 5%+ dividend yield, but declining operating cash flow and bearish technicals suggest near-term headwinds. Risks include regulatory scrutiny and combustible product declines, while analyst consensus leans bullish with 12 buy ratings.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
